Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCR5 | P51681 | 2/20 | 0.52 |
| ▸ | LMNA | P02545 | 2/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.51 |
| ▸ | RAB9A | P51151 | 1/20 | 0.51 |
| ▸ | USP2 | O75604 | 1/20 | 0.51 |
| ▸ | LRRK2 | Q5S007 | 8/20 | 0.48 |
| ▸ | SMPD1 | P17405 | 1/20 | 0.46 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.46 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.46 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.46 |
| ▸ | HTT | P42858 | 2/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.46 |
| ▸ | USP28 | Q96RU2 | 1/20 | 0.46 |
| ▸ | USP25 | Q9UHP3 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16293408 | 1.00 | CCR5 (0.52) | CCR5LMNAALDH1A1RAB9AUSP2 | |
| SCHEMBL16293409 | 1.00 | CCR5 (0.52) | CCR5LMNAALDH1A1RAB9AUSP2 | |
| SCHEMBL16294077 | 0.89 | PTGER1 (0.54) | CCR5LMNAALDH1A1RAB9AUSP2 | |
| SCHEMBL16294377 | 0.89 | PTGER1 (0.54) | CCR5LMNAALDH1A1RAB9AUSP2 | |
| SCHEMBL16294078 | 0.89 | PTGER1 (0.54) | CCR5LMNAALDH1A1RAB9AUSP2 | |
| SCHEMBL1355279 | 0.87 | HTT (0.50) | CCR5LMNAALDH1A1RAB9AUSP2 | |
| SCHEMBL8321821 | 0.83 | CCR5 (0.54) | CCR5LMNAALDH1A1RAB9AUSP2 | |
| SCHEMBL17705192 | 0.82 | CCR5 (0.53) | CCR5LMNAALDH1A1RAB9AUSP2 | |
| SCHEMBL9287833 | 0.82 | HTT (0.46) | CCR5LMNAALDH1A1RAB9AUSP2 | |
| SCHEMBL16306981 | 0.81 | CYSLTR2 (0.51) | LMNAALDH1A1RAB9ASMPD1HTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9657006-B2 | Macrocyclic factor VIIa inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2017-05-23 | — | — | US | disclosed |
| US-9657006-B2 | Macrocyclic factor VIIa inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2017-05-23 | — | — | US | disclosed |
| US-20160115159-A1 | MACROCYCLIC FACTOR VIIA INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2016-04-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160115159-A1 | MACROCYCLIC FACTOR VIIA INHIBITORS | F7, F12, F5 | CCR5 3177/4885LMNA 963/4885ALDH1A1 2603/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.